samedan logo
 
 
spacer
home > pmps > winter 2021 > how technology can help turn the tide on fake drugs in the covid-19 era
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

How Technology Can Help Turn the Tide on Fake Drugs in the COVID-19 Era

It is an unfortunate fact of industry that almost every sector of the global market is plagued by counterfeiting and the proliferation of knock-off products, created and sold by opportunistic or criminal enterprises. However, there are few in which the potential impact is as harmful to people as it is for the pharmaceutical sector.

Buying a fake consumer product is likely to be an expensive inconvenience at worst, but substandard or falsified medicines can pose a genuine threat to human health, as vulnerable patients are left with useless therapies that fail to treat their condition, or actively cause them harm. Against the backdrop of the current COVID-19 pandemic, this is a problem that is accelerating, and the consequences of this trend could be devastating.

To make matters worse, modern counterfeiting techniques are often quite sophisticated, making fake medicines harder than ever to detect, even without the supply chain disruptions brought about by the pandemic. International authorities are dedicating considerable time and resources to tackling the danger posed by counterfeit medicines, but the problem remains prominent.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Seed is a Sales and Product Manager at Elementar UK, a leading supplier of elemental analysis and IRMS (isotope-ratio mass spectrometer) instrumentation. He has been working with the company for nearly two decades, and has significant expertise in the development of stable isotope analysis techniques applied to a broad spectrum of applications.
spacer
Mike Seed
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HEXO and Tilray Brands Agree to Create Strategic Alliance Bringing Together Two Canadian Cannabis Leaders

GATINEAU, Quebec, March 03, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) ("HEXO" or the “Company"), a leading producer of high-quality cannabis products, today announced that the Company has taken a significant step in executing on its strategic plan -The Path Forward - by finalizing a strategic partnership with Tilray Brands, Inc. (“Tilray Brands”) which includes a new debt financing agreement.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement